The effect of the use of melatonin in the treatment of intestinal inflammatory diseases: an integrative review

Authors

  • Rosenely Aline Pereira Ferreira União das Instituições de Serviços, Ensino e Pesquisa
  • Priscila de Sá Ramos União das Instituições de Serviços, Ensino e Pesquisa
  • Angela Alves Salvador União das Instituições de Serviços, Ensino e Pesquisa
  • Arthur Alves Negrão da Silva Faculdades Integradas do Vale do Ribeira
  • Francini Xavier Rossetti Faculdades Integradas do Vale do Ribeira
  • Gislene dos Anjos Tamasia Faculdades Integradas do Vale do Ribeira
  • Mariana Scudeller Vicentini União das Instituições de Serviços, Ensino e Pesquisa
  • Sergio Ricardo Brito Bello Centro Universitário Campos de Andrade

DOI:

https://doi.org/10.33448/rsd-v8i9.1263

Keywords:

Melatonin; Inflammatory Bowel Diseases; Colitis; Tryptophan; Serotonin; Antioxidant.

Abstract

Inflammatory Bowel Diseases (IBD) is characterized by inflammation of the gastrointestinal tract and the two most common types are Crohn's disease (DC) and ulcerative colitis (UC). Both diseases have relapsing immune function. In the extreme context, a melatonin (LMT), is triggered enzymatically from L-tryptophan, has been shown to be a versatile hormone favorable in the treatment of DII disease. Based on the main complications associated with an IBD, the objective of this review is to integrate the decision-making of the main clinical actors related to the use of MLT in the treatment of Crohn's disease (DC) and ulcerative colitis (RCU). For that, an integrative review was performed considering the bibliographies selected in the main databases. The MLT appears to play a significant role in GIT, with no gastrointestinal side effects, with free radical effects, local anti-inflammatory activity, and a moderation of visceral. Thus, it appears to be a promising alternative in the treatment of IBD.

References

Bubenik, G. A. (2002). Gastrointestinal melatonin: localization, function, and clinical relevance. Digestive diseases and sciences, 47(10), 2336–2348.

Centro de Diagnóstico de Gastroenterologia. (2018). Síndrome do Intestino Irritável (SII). Disponível em: <http://www.clinicacedig.com.br/dicas/orientacao/item/sindrome-intestino-irritavel-sii.html>. Acesso em: 04 abr 2019.

Chen, C.-Q., Fichna, J., Bashashati, M., Li, Y.-Y., & Storr, M. (2011). Distribution, function and physiological role of melatonin in the lower gut. World journal of gastroenterology: WJG, 17(34), 3888-3898.

Chojnacki, C., Wisniewska-Jarosinska, M., Walecka-Kapica, E., Klupinska, G., Jaworek, J., & Chojnacki, J. (2011). Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. Journal of physiology and pharmacology, 62(3), 327-334.

Chojnacki, Cezary, Blasiak, J., Fichna, J., Chojnacki, J., & Poplawski, T. (2018). Evaluation of Melatonin Secretion and Metabolism Exponents in Patients with Ulcerative and Lymphocytic Colitis. Molecules, 23(2), 272.

Chojnacki, Cezary, Wiśniewska-Jarosińska, M., Kulig, G., Majsterek, I., Reiter, R. J., & Chojnacki, J. (2013). Evaluation of enterochromaffin cells and melatonin secretion exponents in ulcerative colitis. World Journal of Gastroenterology: WJG, 19(23), 3602.

Fernandez, V. (2012). Efeitos da administração de melatonina sobre a resposta imune em ratos Wistar na amebíase hepática (Dissertação de Mestrado). Universidade de São Paulo, Ribeirão Preto, SP, Brasil.

França-Botelho, A. C., França, J. L., Oliveira, F. M., Franca, E. L., Honório-França, A. C., Caliari, M. V., & Gomes, M. A. (2011). Melatonin reduces the severity of experimental amoebiasis. Parasites & vectors, 4(1), 62.

Hardeland, R. (2018). Melatonin and inflammation—Story of a double-edged blade. Journal of pineal research, 65(4), e12525.

Kasimay, Ö., Cakir, B., Devseren, E., & Yegen, B. C. (2005). Exogenous melatonin delays gastric emptying rate. Journal of physiology and pharmacology, 56(4), 543–553.

Konturek, S. J., Konturek, P. C., Brzozowski, T., & Bubenik, G. A. (2007). Role of melatonin in upper gastrointestinal tract. Journal of physiology and pharmacology, 58(6), 23–52.

Lee, J. H., Yun, C. W., Han, Y.-S., Kim, S., Jeong, D., Kwon, H. Y., … Lee, S. H. (2018). Melatonin and 5-fluorouracil co-suppress colon cancer stem cells by regulating cellular prion protein-Oct4 axis. Journal of pineal research, 65(4), e12519.

Mauriz, J. L., Collado, P. S., Veneroso, C., Reiter, R. J., & González-Gallego, J. (2013). A review of the molecular aspects of melatonin’s anti-inflammatory actions: recent insights and new perspectives. Journal of pineal research, 54(1), 1–14.

Mendes, K. D. S., Silveira, R. C. de C. P., & Galvão, C. M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto enfermagem, 17(4), 758–764.

Saha, L., Malhotra, S., Rana, S., Bhasin, D., & Pandhi, P. (2007). A preliminary study of melatonin in irritable bowel syndrome. Journal of clinical gastroenterology, 41(1), 29–32.

Sánchez, A., Calpena, A., & Clares, B. (2015). Evaluating the oxidative stress in inflammation: role of melatonin. International journal of molecular sciences, 16(8), 16981–17004.

Siah, K. T. H., Wong, R. K. M., & Ho, K. Y. (2014). Melatonin for the treatment of irritable bowel syndrome. World journal of gastroenterology: WJG, 20(10), 2492-2498.

Sociedade Brasileira de Endocrinologia e Metabologia. (2016). Posicionamento da SBEM sobre a melatonina. Rio de Janeiro. Disponível em: < https://www.endocrino.org.br/media/uploads/PDFs/posicionamento_sobre_melatonina_sbem.pdf> Acesso em 22 set 2018.

Tas, U., Ayan, M., Sogut, E., Kuloglu, T., Uysal, M., Tanriverdi, H. I., … Sarsilmaz, M. (2015). Protective effects of thymoquinone and melatonin on intestinal ischemia–reperfusion injury. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, 21(5), 284-289.

Tasdemir, S., Parlakpinar, H., Vardi, N., Kaya, E., & Acet, A. (2013). Effect of endogen-exogenous melatonin and erythropoietin on dinitrobenzene sulfonic acid–induced colitis. Fundamental & clinical pharmacology, 27(3), 299–307.

Terry, P. D., Villinger, F., Bubenik, G. A., & Sitaraman, S. V. (2008). Melatonin and ulcerative colitis: evidence, biological mechanisms, and future research. Inflammatory bowel diseases, 15(1), 134–140.

Trivedi, P. P., & Jena, G. B. (2013). Melatonin reduces ulcerative colitis-associated local and systemic damage in mice: investigation on possible mechanisms. Digestive diseases and sciences, 58(12), 3460–3474.

Trivedi, P. P., Jena, G. B., Tikoo, K. B., & Kumar, V. (2016). Melatonin modulated autophagy and Nrf2 signaling pathways in mice with colitis-associated colon carcinogenesis. Molecular carcinogenesis, 55(3), 255–267.

Zenteno, M. E. (2015). Efeito da melatonina no desenvolvimento da resposta imune mediada por linfócitos T CD4. (Tese de doutorado). Universidade de São Paulo, Instituto de Ciências Biomédicas, São Paulo, SP, Brasil.

Zhu, D., Ma, Y., Ding, S., Jiang, H., & Fang, J. (2018). Effects of melatonin on intestinal microbiota and oxidative stress in colitis mice. BioMed research international, 2018.

Zielińska, M., Jarmuż, A., Salaga, M., Kordek, R., Laudon, M., Storr, M., & Fichna, J. (2016). Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice. Naunyn-Schmiedeberg’s archives of pharmacology, 389(5), 511–519.

Downloads

Published

14/06/2019

How to Cite

FERREIRA, R. A. P.; RAMOS, P. de S.; SALVADOR, A. A.; SILVA, A. A. N. da; ROSSETTI, F. X.; TAMASIA, G. dos A.; VICENTINI, M. S.; BELLO, S. R. B. The effect of the use of melatonin in the treatment of intestinal inflammatory diseases: an integrative review. Research, Society and Development, [S. l.], v. 8, n. 9, p. e17891263, 2019. DOI: 10.33448/rsd-v8i9.1263. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/1263. Acesso em: 26 nov. 2024.

Issue

Vol. 8 No. 9

Section

Health Sciences

License

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.